This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to...
AstraZeneca presented new data underpinning the safety profile of Farxiga (dapagliflozin) with an analysis of data pooled from dapagliflozin clinical...
The primary efficacy objective is to determine whether treatment with dapagliflozin compared with placebo when added to current background therapy...
Dapagliflozin is a highly selective, reversible and potent inhibitor of the sodium-glucose-linked Transporter 2 (SGLT2), which was successfully investigated for...
AstraZeneca and Bristol-Myers Squibb Company announced that the FDA has acknowledged receipt of the New Drug Application (NDA) resubmission for...
In the Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in CKD patients with or without type 2 diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to...
Obesity is a medical condition which increases the risk of other diseases, such as type 2 diabetes and cardiovascular disease....
The purpose of this study is to learn if BMS-512148 (dapagliflozin) as part of a triple combination therapy can improve...
A combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin...